Gastrointestinal tumours, non-colorectal
Gastrointestinal tumours, non-colorectal: Invited Discussant 620PD, 621PD, 622PD and 623PD
Date
11 Sep 2017Session
Gastrointestinal tumours, non-colorectalPresenters
Stefano CascinuAuthors
S. CascinuAuthor affiliations
- Department Of Oncology , AOU Ospedali Riuniti Ancona Università Politecnica delle Marche, 60126 - Ancona/IT
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
2143 - YOSEMITE: A 3 Arm Double-Blind Randomized Phase 2 Study of Gemcitabine, Paclitaxel Protein-Bound Particles for Injectable Suspension (Abraxane®) and Placebo (GAP) versus Gemcitabine, Abraxane® and either 1 or 2 Truncated Courses of Demcizumab (GAD).
Presenter: Antonio Cubillo Gracian
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
2743 - A Phase 2b of eryaspase in combination with gemcitabine or FOLFOX as second-line therapy in patients with metastatic pancreatic adenocarcinoma (NCT02195180)
Presenter: Pascal Hammel
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3096 - nab-Paclitaxel (nab-P) Plus Gemcitabine (G) for Patients (Pts) With Locally Advanced Pancreatic Cancer (LAPC): Interim Efficacy and Safety Results From the Phase 2 LAPACT Trial
Presenter: Philip Philip
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
1091 - A phase I and randomized phase II trial to evaluate the efficacy and safety of nab-paclitaxel (nab-P) in combination with gemcitabine (G) for the treatment of patients with ECOG 2 advanced pancreatic cancer (PDAC).
Presenter: Manuel Hidalgo
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
Slides
5988 - New promising combination therapy of a mitochondrial metabolism inhibitor with mFOLFIRINOX in pancreatic cancer
Presenter: Angela Alistar
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
5986 - Anti-CTGF human recombinant monoclonal antibody pamrevlumab increases resectability and resection rate when combined with gemcitabine/Nab-paclitaxel in the treatment of locally advanced pancreatic cancer patients
Presenter: Ewa Carrier
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
2205 - A phase III trial of muparfostat (PI-88) as adjuvant therapy in patients with hepatitis virus related hepatocellular carcinoma (HV-HCC) after resection
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
2539 - Protein biomarkers as predictors of outcome with regorafenib (REG) in patients (pts) with hepatocellular carcinoma (HCC) in the RESORCE trial
Presenter: Michael Teufel
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
937 - A randomized phase III trial comparing 4 courses and 8 courses of S-1 adjuvant chemotherapy for p-stage II gastric cancer: JCOG1104 (OPAS-1)
Presenter: Takaki Yoshikawa
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract
3861 - Comparison of the eighth and seventh editions of the American Joint Committee on Cancer TNM staging systems for gastric cancer: proposal for a simplified and improved TNM staging system
Presenter: Junpeng Lin
Session: Gastrointestinal tumours, non-colorectal
Resources:
Abstract